Talk:MasSpec Pen

=COI Edit Requests=

Untitled
Hello editors. I am requesting to edit a majority of this Wikipedia page on behalf of Genio Technologies, Inc., the company developing the MasSpec Pen technology, to better reflect the current state of development of the device and correct previous inaccuracies that have occurred on the page. Due to my COI with the company I will not be editing the page directly, and would greatly appreciate the help in editing the page. As I am new to editing, I am open to any discussions and requests from editors and I ask for patients from potential editors. Below are the desired edits:

Below are the references cited throughout the post. I appreciate the edit and please let me know if there are any issues!

Clfeider (talk) 17:05, 7 December 2020 (UTC)


 * Note: As this has received no reply for two months, I've split this up into several separate requests, in the hope that smaller pieces might be easier to process.  WhatamIdoing (talk) 20:56, 13 February 2021 (UTC)

Lead
The MasSpec Pen, or the precìso MasSpec Pen System, is a mass spectrometry (MS) based cancer detection and and diagnosis system that can be used for ex vivo and in vivo tissue sample analysis. The system collects biological molecules from a tissue sample surface via a solid-liquid extraction mechanism and transports the molecules to a mass spectrometer for analysis. The composition of the extracted molecules can then be used to predict if the tissue sample analyzed contains cancerous cells using machine learning algorithms and statistical models. In early-stage clinical research, the MasSpec Pen system was able to distinguish various cancer tissues, including thyroid, breast, lung, and ovarian tumor tissues, from their normal counterparts with an overall accuracy of 96.3%. A follow-up study in illustrating the use of the device for detection of serous ovarian carcinoma in ex vivo tissue biopsies allowed for the discrimination of normal and cancerous ovarian samples with a clinical sensitivity and specificity of 94.0% and 94.4%, respectively.


 * Support: Vastly better sources and content than the current page. CorporateM (Talk) 04:03, 15 February 2021 (UTC)


 * Thank you for your support of this change. I will not be editing the page directly due to my COI, but if this change is supported by you and other Wikipedia editors I would appreciate it being added to the page Clfeider (talk) 17:01, 23 February 2021 (UTC)

NEW SECTION: Development History
Livia S. Eberlin, Ph.D., an Assistant Professor of Chemistry at the University of Texas at Austin and MacArthur "Genius" Fellowship recipient, first reported the invention of the MasSpec Pen in 2017. Within her laboratory, the device has been used to analyze more than 800 ex vivo human tissue biopsies, including normal and cancerous brain, breast, lung, ovarian, pancreas, and thyroid samples. The MasSpec Pen is currently being evaluated for use in oncology surgeries at the Texas Medical Center in Houston, Texas.

The MasSpec Pen, which has been renamed as the precìso MasSpec Pen System, is currently being developed by Genio Technologies, Inc., a medical device and diagnostics company. The device is currently for research use only and is not been approved by the FDA as a medical device.

Clfeider (talk) 17:05, 7 December 2020 (UTC)


 * Oppose: Plugging awards for the founder is inappropriate. The Science Daily citations appears to be a short blurb. Naming customers/users is usually seen as promotional. External links in the body of the page is generally prohibited. I have no connection to the article-subject.  CorporateM (Talk) 04:06, 15 February 2021 (UTC)


 * Thank you for your feedback on these changes. I completely understand the concerns. Below I have included a modified version of this section that I hope will be more appropriate. The changes include:
 * Removing the reference to the MacArthur Award
 * Removed the citation to the ACS blurb and modified the sentence so that it could be supported by academic publications cited within the article
 * Removing the reference to the Texas Medical Center
 * Adding a citation for a recent manuscript published in the medRxiv regarding the analysis of samples in vivo during oncology surgeries
 * Removing the direct link to the website for the technology and replacing with a citation to a webpage describing the licensing of the technology to Genio Technologies Inc. I am aware that this is a link to a press release, but there has been a significant amount of misinformation on this page stating the system was licensed to Abbott. It would be best to provide some information about the true licensor of the technology to prevent future incorrect information being added to the page, but I am unable to find additional sources that contains this information. If this cannot be included in the article, I understand


 * Livia S. Eberlin, Ph.D., an Assistant Professor of Chemistry at the University of Texas at Austin, first reported the invention of the MasSpec Pen in 2017. Within her laboratory, the device has been used to analyze  human tissue biopsies, including normal and cancerous breast, lung, ovarian, and thyroid samples.  The MasSpec Pen is currently being evaluated for use on freshly excised tissue biopsies and for intraoperative use during oncology surgeries.


 * The MasSpec Pen has been licensed to Genio Technologies, Inc., a subsidiary of MS Pen Technologies, Inc.

Clfeider (talk) 17:50, 23 February 2021 (UTC)

Ambient ionization mass spectrometry for disease diagnosis
The MasSpec Pen technology is based on the principles of ambient ionization, in which ions are generated directly from a sample without need for extensive sample preparation or chromatographic separations. The MasSpec Pen can further be categorized as a solid-liquid extraction based ambient ionization method, described as methods that utilize a solvent system to gently extract molecules from a sample surface that are subsequently analyzed by a mass spectrometer. Desorption electrospray ionization (DESI) was the first liquid-based ambient ionization MS method. DESI employed a spray of charged solvent droplets to bombard a sample surface to desorb and ionize molecules from the sample surface, which are then directed towards and analyzed by a mass spectrometer. DESI-MS and other solvent-based ambient ionization MS methods has been widely employed for the analysis of small molecules, primarily metabolites and lipids, directly from biological tissue specimens to determine their molecular composition and leverage the mass spectral data acquired for diagnostic purposes. These methods have been deployed for the discrimination of normal and cancerous regions of tissue samples for many solid tumor indications, including breast, brain   , prostate  , ovarian  , and colorectal , among others. Multivariate statistical analysis methods are often utilized to generate statistical models from the mass spectral data acquired from direct analysis of tissue samples to distinguish between healthy and diseased tissues.

MasSpec Pen analysis mechanism
The MasSpec Pen, initially described in 2017, is a solvent-based ambient ionization technique but differs from its predecessors due to the handheld nature of the device, allowing analysis of samples distant from the mass spectrometer in a geometry independent manner. The MasSpec Pen used a probe that can manipulated by hand to direct the analysis. To use the system, the tip of the 'pen' is placed in contact with the surface to be sampled and the user triggers the initiation of a sampling procedure by pressing an integrated foot pedal. This signal a syringe pump to deliver a small aliquot of solvent through a polymer tube to a reservoir at the tip of the 'pen' that remains in contact with the sample. Analytes are then extracted from the sample into the solvent droplet by a solid-liquid extraction mechanism. After a 3 second extraction period, the droplet is aspirated into the mass spectrometer using the vacuum from the mass spectrometer as the vacuum source. Once inside the mass spectrometer, the analytes within the solvent droplet are de-solvated and ionized via an inlet ionization mechanism. The ionized molecules are then analyzed by the mass spectrometer analyzer and the mass spectrum resulting is generated.

Cancer diagnosis with the MasSpec Pen
The MasSpec Pen was designed to assist in the detection of positive surgical margins during solid tumor debulking procedures to assist in the complete excision of cancer surgeries. The device was initially used to analyze 253 human tissue biopsies, including normal and cancerous breast, lung, ovary, and thyroid tissues. The mass spectra obtained for each sample contained metabolites, lipids, and some proteins that were representative of the molecular composition of the tissue analyzed. The collected data for each tissue type was then used to develop statistical models that could discriminate between the normal and cancer samples of each tissue type. Leave-one-patient-out cross validation was used to evaluate the accuracy of the models for distinguishing the normal and cancer tissues based on their molecular profiles. The method allowed for diagnosis of the breast tissues with 95.6% accuracy, lung with 96.8% accuracy, and ovary with 94.7% accuracy. Statistical models also allowed for the discrimination of normal thyroid from papillary thyroid carcinomas with 97.8% accuracy and from follicular thyroid adenomas with 94.7% accuracy. The report also demonstrated the ability of the MasSpec Pen technology to detect cancer within regions of mixed tissue containing both normal and cancerous cells from an ovarian cancer sample. Finally, the authors demonstrated the use of this method for in vivo analysis of tumor tissues using an anesthetized murine model.

Performance of the MasSpec Pen for ovarian cancer diagnosis was further evaluated in a report published in 2019. The authors analyzed 160 human ovarian tissue samples, including 78 normal ovary and 82 serous carcinomas, with the MasSpec Pen and developed classification models to discriminate between the normal and cancer samples. The model was able to distinguish between the normal and cancerous ovarian samples with 98.3%, 100.0%, and 92.3% overall accuracy on a training, validation, and test set of samples. Further, the report evaluated the ability of the MasSpec Pen system to distinguish ovarian cancer from fallopian tube and peritoneum tissue, two of the most common sites for ovarian cancer metastasis. Accuracies of 87.9% and 92.6% were achieved for the discrimination of cancer from fallopian tube and peritoneum tissues, respectively.

Clfeider (talk) 17:05, 7 December 2020 (UTC)


 * Support with modifications: Suggest removing all unsourced content and implementing the rest. It is too technical for the general reader audience Wikipedia is intended for, but adequate as a starting point and an improvement over having nothing. I have no connection to the article subject. CorporateM (Talk) 04:09, 15 February 2021 (UTC)


 * Thank you for your response to my edits. If other editors have input on what can be removed to improve sourcing and readability, I would be extremely grateful. The information provided in this section is provided only from peer-reviewed articles, but I can modify the placement of citations if the material appears unsourced. Once approved by editors, I would appreciate this information being added to the main article. Clfeider (talk) 18:30, 23 February 2021 (UTC)

September 2021 Edit Request
Hello Wikipedia Editors! I'm requesting a few edits on behalf of Genio Technologies, Inc. I am a paid consultant for the company and will not be implementing the following edits myself. I appreciate those willing to review and implement the following changes!

Clfeider (talk)

Lead
Addition of the MasSpec Pen photo. This image has been uploaded by the owner under a Creative Commons Attribution-ShareAlike 4.0 International license.



Within the "Cancer Diagnosis with the MasSpec Pen" Section
The MasSpec Pen has also been implemented for the detection of pancreatic cancer during excision procedures. The MasSpec Pen was used on both ex vivo and in vivo tissue samples to discriminate between healthy pancreas and pancreatic tumor tissue. The device was also used to detect cancerous margins near adjacent structures of the pancreas such as the bile duct. The system was used in 18 pancreatic cancer surgeries and the data collected allowed the detection of cancerous tissue with high accuracy.

References:
There is an updated citation for reference 3:
 * ✅. Heartmusic678 (talk) 15:09, 8 December 2021 (UTC)